{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010342","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.613816+00:00","generated_at":"2026-05-16T10:52:36.646632+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA issues CRL for Atara's EBVALLO BLA, reversing prior stance on trial adequacy","bullets":["FDA CRL received Jan 9, 2026; confirms GMP issues resolved but claims ALLELE trial inadequate for accelerated approval.","Atara and partner Pierre Fabre plan to request Type A meeting within 45 days to seek path forward.","Cash, cash equivalents and short-term investments as of Dec 31, 2025: approximately $8.5M.","Atara implemented ~90% headcount reduction and reduced ARC lease liability by ~65% in 2025.","Amendment to PFM agreement: approval milestone reduced to $31M, with potential $15M commercial milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010342","json":"https://secwatch.observer/filing/0001193125-26-010342.json","markdown":"https://secwatch.observer/filing/0001193125-26-010342.md","text":"https://secwatch.observer/filing/0001193125-26-010342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/0001193125-26-010342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000119312526010342/d34257d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:52:36.646632+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}